Abstract: The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.
Type:
Grant
Filed:
December 1, 2016
Date of Patent:
September 22, 2020
Assignees:
The Procter & Gamble Company, The Cleveland Clinic Foundation
Inventors:
Stanley Leon Hazen, Jose Carlos Garcia-Garcia, George Franklin Gerberick, John August Wos, David Thomas Stanton, Thomas Alfred Inglin, Michael Reilly, Angela Jane Deutsch, Jodie Michele Reed, David Blair Cody
Abstract: This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.
Type:
Grant
Filed:
May 2, 2016
Date of Patent:
September 15, 2020
Assignees:
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC., EMORY UNIVERSITY
Inventors:
Binghe Wang, Erwin Van Meir, Jalisa Holmes Ferguson, Stefan Kaluz, Xingyue Ji
Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
September 8, 2020
Inventors:
Henry Lowe, Ngeh J. Toyang, Joseph Bryant
Abstract: Disclosed are compounds that are shown to inhibit the biological activity of nitric oxide synthases (NOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. Because the disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs), the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with NOS activity.
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
September 1, 2020
Assignee:
Northwestern University
Inventors:
Richard B. Silverman, Heng-Yen Wang, Yajuan Qin, Fengwei Zou, Soo Sung Kang, Qing Jing
Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
Abstract: The invention provides compositions and unit dosage forms that are effective to improve sexual performance. Such compositions and unit dosage forms are useful to increase duration of sexual intercourse, satisfaction with sexual intercourse, and improve erectile function in men.
Abstract: The invention provides—opioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, hypotension, and post-treatment withdrawal symptoms.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
August 25, 2020
Assignee:
THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Thomas D. Bannister, Laura M. Bohn, Cullen L. Schmid
Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, L1, L2, E, X, Y, Z, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
August 11, 2020
Assignee:
ARAXES PHARMA LLC
Inventors:
Liansheng Li, Jun Feng, Tao Wu, Yuan Liu, Yi Wang, Pingda Ren, Yi Liu
Abstract: Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.
Abstract: The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
Type:
Grant
Filed:
January 27, 2017
Date of Patent:
July 14, 2020
Assignee:
UNIVERSITY OF MISSISSIPPI
Inventors:
Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
July 7, 2020
Assignee:
The Regents of the University of California
Inventors:
Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
Abstract: The present disclosure provides a method of treating a patient with refractory or resistant cancer by administering a therapeutically effective amount of a compound of formula (I), such as Varlitinib, or an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same. Also provided is a compound of formula (I) for use in the treatment of resistant or refractory cancer and use of a compound of formula (I) for the manufacture of a medicament for the treatment of resistant or refractory cancer.
Abstract: The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the ?-amyloid protein (A?) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of A? in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered.
Type:
Grant
Filed:
July 28, 2014
Date of Patent:
June 16, 2020
Assignee:
EVERFRONT BIOTECH INC.
Inventors:
Hong-Lin Su, Chia-Yu Chang, Shiaw-Min Hwang, Huai-En Lu, Horng-Jyh Harn, Shinn-Zong Lin, Ping-Shan Lai
Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
Abstract: A method for preventing or treating immunoinflammatory dermal disorders is provided. Also provided is a pharmaceutical composition for preventing or treating immunoinflammatory dermal disorders.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
June 9, 2020
Assignee:
TWi Biotechnology, Inc.
Inventors:
Po-Yuan Tseng, Wei-Shu Lu, Carl Oscar Brown, III, I-Yin Lin, III, Chen-En Tsai, Chih-Kuang Chen
Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
Type:
Grant
Filed:
July 2, 2014
Date of Patent:
May 26, 2020
Assignee:
ACTELION PHARMACEUTICALS LTD
Inventors:
Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
May 26, 2020
Assignee:
Syntrix Biosystems Inc.
Inventors:
John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
Abstract: The present invention provides joint use of stain and adrenocortical hormone for preparing a pharmaceutical product for the treatment of chronic subdural hematoma. The pharmaceutical product according to the present invention is capable of accelerating hematoma absorption and improving a therapeutic effect of single oral administration of a statin-based pharmaceutical product, and the dose of the adrenocortical hormone-based pharmaceutical product used is 1/10 of the dose used in a large-dose hormonal therapy.
Type:
Grant
Filed:
December 29, 2016
Date of Patent:
May 12, 2020
Inventors:
Jianning Zhang, Rongcai Jiang, Dong Wang
Abstract: The present invention relates to compositions providing improved preservative efficacy. The present invention further relates to polyquaternium compound containing compositions having improved the antifungal activity. In certain embodiments, the present invention relates to ophthalmic compositions comprising a polyquaternium compound, a polyol or combination of polyols, borate compound, and an antimicrobial mixture comprising electrolytes and nutrients.